News

Does Valve Repair Approval Change The Bull Case For Edwards Lifesciences (EW)?

Edwards Lifesciences reported past FDA approvals for its PASCAL Precision system for tricuspid valve repair and PASCAL Ace with Capture Clarity for degenerative mitral TEER, giving the business a broader U.S. transcatheter repair toolkit for patients who are not good candidates for open heart surgery. The combination of tricuspid and mitral TEER approvals makes Edwards Lifesciences the only supplier offering both repair and replacement transcatheter options across these valves in the U.S.,...

Yahoo·07:18EW

Edwards wins FDA approval for tricuspid valve repair device

Edwards’ approval should “strengthen the company’s position in the large and underpenetrated transcatheter tricuspid market,” analysts said.

Yahoo·06:20EW

DaVita Stock Gains 55.6% Year to Date: What's Behind the Rally?

DaVita's 55.6% stock rally reflects stronger operating execution, improving treatment volumes and value-based kidney care gains despite reimbursement pressures.

Yahoo·13:38

Is This the Right Time to Hold EW Stock in Your Portfolio?

Edwards Lifesciences' TMTT and TAVR growth, strong clinical evidence and solid balance sheet support expansion, but tariffs and currency headwinds threaten margins.

Yahoo·07:48EW

Edwards secures FDA approval for tricuspid valve repair system

The PASCAL Precision device is indicated to treat individuals with symptomatic severe tricuspid regurgitation.

Yahoo·05:15EW

FDA Approval of Edwards Lifesciences’ PASCAL Precision System Opens New Treatment Pathway for Patients With Tricuspid Valve Disease

IRVINE, Calif., October 21, 2026--Edwards Lifesciences Corporation (NYSE: EW) today announced that the U.S. Food and Drug Administration (FDA) has approved its PASCAL Precision system for tricuspid valve repair. The system is indicated for improving quality of life and functional status in patients with symptomatic severe tricuspid regurgitation (TR) despite optimal medical therapy who are deemed at intermediate or greater risk for surgery and deemed appropriate for transcatheter edge-to-edge tr

Yahoo·09:00EW

FDA Flags High-Risk Heart Device Recall At Edwards Lifesciences After Patient Death

The U.S. Food and Drug Administration (FDA) issued a high-risk early alert after Edwards Lifesciences Corp. (NYSE:EW) recalled specific lots of its Commander M delivery systems due to reports of balloons bursting during procedures, resulting in one death and a serious injury. Recall Of Commander M Delivery Systems The delivery systems help implant a replacement mitral heart valve through blood vessels, bypassing the need for open-chest surgery. However, the company received three distinct report

Yahoo·11:13EW

Edwards’ SAPIEN M3 delivery system linked to patient death in FDA alert

An issue with the delivery component of Edwards’ SAPIEN M3 TMVR system has been associated with one patient death and one serious injury as of 5 October.

Yahoo·07:47EW

Reported Earlier, Edwards Lifesciences Tells Customers To Remove Four Lots Of Commander M Delivery Systems For SAPIEN M3; FDA Flags Potentially High-Risk Issue

https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-transcatheter-mitral-valve-delivery-system-issue-edwards-lifesciences

Benzinga·23:50EW

Bet on These Healthcare ETFs to Benefit From the Aging US Population

With the US population aging rapidly, three healthcare ETFs offer exposure to companies developing treatments, drugs and medical devices for age-related conditions.

Yahoo·08:09

Edwards Lifesciences Earnings Preview: What to Expect

Edwards Lifesciences is set to report its Q3 earnings next month, with analysts expecting single-digit year-over-year EPS growth.

Yahoo·04:56EW

Stay informed with the top movers within the S&P500 index on Thursday.

Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Thursday as we examine the latest happenings in today's session.

ChartMill·12:35

Barclays Initiates Coverage of Edwards Lifesciences at Overweight

Fintel·19:52EW

Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026

IRVINE, Calif., October 07, 2026--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended Sept. 30, 2026 after the market closes on Wednesday, Nov. 4, and will host a conference call at 5:00 p.m. ET that day to discuss those results.

Yahoo·06:00EW

Barclays Initiates Coverage On Edwards Lifesciences with Overweight Rating, Announces Price Target of $110

Barclays analyst Christopher Pasquale initiates coverage on Edwards Lifesciences (NYSE:EW) with a Overweight rating and announces Price Target of $110.

Benzinga·04:40EW

Edwards Lifesciences to Host Investor Event in Conjunction With TCT

IRVINE, Calif., October 05, 2026--Edwards Lifesciences (NYSE: EW) today announced that it will host an investor event in conjunction with the TCT annual scientific symposium in San Diego on Monday, Nov. 2, from 5:00 to 6:00 PM Pacific Time. The meeting will include a live Q&A session with physicians and members of the Edwards management team.

Yahoo·06:00EW

Edwards Lifesciences Secures FDA Approval for First Expandable Pediatric Heart Valve

Edwards Lifesciences earned FDA approval for its AUTUS pediatric heart valve, designed to expand as young patients grow.

Benzinga·06:46EW

Nike, Synaptics And 3 Stocks To Watch Heading Into Friday

Nike falls on weak revenue; Synaptics jumps on $123 ON deal; AsiaStrategy surges on tokenization pact; Mangoceuticals drops.

Benzinga·00:16

Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients

IRVINE, Calif., October 01, 2026--Edwards Lifesciences (NYSE: EW) today announced that the U.S. Food and Drug Administration (FDA) has approved the AUTUS Size-Adjustable Valve, a surgical pulmonary valve designed specifically for pediatric patients with congenital heart disease who require pulmonary valve replacement.

Yahoo·16:26EW

Edwards Lifesciences Says FDA Approves AUTUS Size-Adjustable Valve, Surgical Pulmonary Valve Designed For Pediatric Patients With Congenital Heart Disease

Edwards Lifesciences (NYSE:EW) today announced that the U.S. Food and Drug Administration (FDA) has approved the AUTUS Size-Adjustable Valve, a surgical pulmonary valve designed specifically for pediatric patients with

Benzinga·12:27EW

How Investors May Respond To Edwards Lifesciences (EW) Expanded TAVR Access And Transcatheter Valve Ambitions

Edwards Lifesciences recently outlined its structural heart growth plan, emphasizing transcatheter valve platforms such as TAVR and TMTT, alongside the impact of updated Medicare coverage that could enable 100–200 additional U.S. centers to perform TAVR procedures. A particularly important takeaway is Edwards’ ambition to build a multibillion-dollar transcatheter mitral and tricuspid business by 2030, anchored by PASCAL, EVOQUE, and Sapien M3 technologies that aim to address complex...

Yahoo·18:15EW

Edwards Lifesciences (EW) Stock Looks Reasonable After Medicare TAVR Expansion

Edwards Lifesciences has delivered a mixed share price story, with the stock up 18.4% over the past year but still down sharply over a 5 year span. This puts the focus squarely on what investors are paying for its future cash flows. With fresh policy news around its core heart valve franchise and a current share price of US$88.25, the key issue is whether the company’s cash generation can support where the stock trades today. Over 5 years the share price has declined 27.1%, which raises the...

Yahoo·14:12

Edwards Lifesciences Sees TAVR Expansion, $2B TMTT Opportunity Ahead

Edwards Lifesciences (NYSE:EW) outlined a strategy centered on structural heart disease, with Chief Executive Officer Bernard Zovighian highlighting five therapy areas that the company views as its principal growth platforms: transcatheter aortic valve replacement for aortic stenosis, PASCAL, EVOQUE

Yahoo·07:02EW

Edwards Lifesciences Corporation (EW) Presents at Deutsche Bank 2026 Healthcare Summit Transcript

Edwards Lifesciences Corporation (EW) Deutsche Bank 2026 Healthcare Summit September 16, 2026 10:00 AM EDTCompany ParticipantsBernard Zovighian - CEO &...

SeekingAlpha·09:01EW

$100 Invested In Edwards Lifesciences 20 Years Ago Would Be Worth This Much Today

Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 20 years by 7.57% on an annualized basis producing an average annual return of 16.73%. Currently, Edwards Lifesciences has a market capitalization

Benzinga·14:30EW

BTIG Reiterates Buy on Edwards Lifesciences, Maintains $110 Price Target

BTIG analyst Marie Thibault reiterates Edwards Lifesciences (NYSE:EW) with a Buy and maintains $110 price target.

Benzinga·01:57EW

Edwards Lifesciences Comments on TAVR National Coverage Decision

IRVINE, Calif., September 10, 2026--Edwards Lifesciences (NYSE: EW) today issued the following statement in response to the national coverage determination (NCD) for transcatheter aortic valve replacement (TAVR) released by the Centers for Medicare & Medicaid Services (CMS):

Yahoo·17:49EW

Edwards Lifesciences: $20 Billion TAM And A Meaningful Opportunity To Compound

Baron Asset Fund initiated a position in Edwards Lifesciences due to its dominant heart valve market share. Read the full analysis for more details.

SeekingAlpha·23:10EW

Pacific Biosciences (PACB) Up 11.6% Since Last Earnings Report: Can It Continue?

Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo·11:30

Edwards Lifesciences to Present at the Deutsche Bank Healthcare Summit

IRVINE, Calif., September 02, 2026--Edwards Lifesciences Corporation (NYSE: EW) will participate in the Deutsche Bank Healthcare Summit on Wednesday, Sept. 16, 2026.

Yahoo·17:15EW

Why Is ISRG Investing More Aggressively in R&D Despite Macro Headwinds?

Intuitive Surgical is boosting R&D despite macro headwinds, targeting AI, robotics and new procedures to expand its market and drive long-term growth.

Yahoo·12:02

Unusual Volume in Edwards Lifesciences Put Options Shows Investors Bullish on EW Stock

An unusually high volume of out-of-the-money (OTM) put options in Edwards Lifesciences (EW) shows investors are bullish on EW stock over the next three months. Moreover, EW is below analysts' price targets.

Yahoo·14:30EW

Edwards Lifesciences (EW): The Medical Device Leader Behind the TAVR Boom

Aristotle Capital Management, LLC, an investment management company, released its “Value Equity Fund” Q2 2026 investor letter. A copy of the letter can be downloaded here. The Fund delivered a 4.32% total return in Q2 2026, underperforming the 13.87% gain for the Russell 1000 Value Index and the 15.20% return for the S&P 500, while […]

Yahoo·13:41EW

Insider Move: Daveen Chopra Exercises Options, Realizing $551K At Edwards Lifesciences

Disclosed in a recent SEC filing on August 26, Chopra, CVP at Edwards Lifesciences (NYSE:EW), made a noteworthy transaction involving the exercise of company stock options. What Happened: The latest Form 4 filing on

Benzinga·07:02EW

MDT's Q1 Earnings on Deck: How Should You Play the Stock Now?

Medtronic's Q1 results may reflect strong growth across Cardiovascular, Neuroscience and Diabetes, but earnings beat signals remain mixed.

Yahoo·10:53

Is Edwards Lifesciences (EW) A Bargain Following Its Asia Pacific Patient Experience Event?

Edwards Lifesciences (EW) recently held its annual Asia Pacific Patient Experience event, spotlighting patient and caregiver perspectives on structural heart disease. For investors, the gathering raises questions about how patient engagement connects to Edwards Lifesciences stock. See our latest analysis for Edwards Lifesciences. At a share price of $89.83, Edwards Lifesciences has seen a 6.24% 30 day share price return and a 4.72% 90 day share price return, while the 1 year total shareholder...

Yahoo·20:12EW

Should You Hold Edwards Lifesciences Stock in Your Portfolio?

EW's TAVR and TMTT growth support its outlook, but currency pressure and intense competition remain key risks.

Yahoo·11:44EW

Edwards Lifesciences (EW) Stock Could Be 1% Above Fair Value On Cash Flow And Earnings

Edwards Lifesciences stock has delivered a 21.6% gain over the past three years, yet the valuation checks paint a less generous picture. The intrinsic value estimate from a Discounted Cash Flow (DCF) model indicates the shares are roughly fairly valued, while traditional market multiples lean expensive. Over the last three years, Edwards Lifesciences has returned 21.6%, which rewards patient holders but leaves fresh buyers needing to judge how much upside is left at today’s...

Yahoo·04:10EW

Here’s How Much You Would Have Made Owning Edwards Lifesciences Stock In The Last 20 Years

Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 20 years by 7.93% on an annualized basis producing an average annual return of 17.22%. Currently, Edwards Lifesciences has a market capitalization

Benzinga·08:00EW

Putting Patients at the Heart of Innovation: Voices Across Asia Pacific Help Shape the Future of Structural Heart Care

As structural heart disease continues to impact a growing number of people across Asia Pacific amid a rapidly ageing population, Edwards Lifesciences (Edwards) brought together patients for its annual Asia-Pacific Patient Experience event. The programme created a platform for patients, caregivers, healthcare professionals and employees to share perspectives, foster meaningful connections and deepen understanding of the patient journey.

Yahoo·06:00EW

9 Health Care Stocks Whale Activity In Today’s Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often

Benzinga·09:35

$100 Invested In Edwards Lifesciences 15 Years Ago Would Be Worth This Much Today

Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 15 years by 1.31% on an annualized basis producing an average annual return of 15.06%. Currently, Edwards Lifesciences has a market capitalization

Benzinga·13:45EW

Edwards Climbs 14% in 3 Months as Growth Strength Tests Valuation

Edwards' 14% three-month rally reflects broad structural-heart growth, but its premium valuation raises the bar for execution.

Yahoo·08:51EW

Is Wall Street Bullish or Bearish on Edwards Lifesciences Stock?

Though Edwards Lifesciences has underperformed the broader market over the past year, Wall Street analysts maintain a strongly optimistic outlook on the stock’s prospects.

Yahoo·09:01EW

Edwards Lifesciences: Strong Execution, But Little Room For Error At $90

SeekingAlpha·05:48EW

Edwards Lifesciences: Cheap Against Itself, Expensive Against Everything Else

Edwards Lifesciences' Q2 saw 13.6% YoY sales growth, but Q3 guidance implies a sequential decline attributed to tough comps, not demand. Read more on EW stock here.

SeekingAlpha·23:55EW

Can da Vinci 5 Drive Intuitive Surgical's Next Multi-Year Upgrade Cycle?

Intuitive Surgical's da Vinci 5 is gaining rapid adoption, fueling hospital upgrades as software enhancements build a potential multi-year capital cycle.

Yahoo·11:41

Aristotle Value Equity WM Q2 2026 Portfolio Performance

For the second quarter of 2026, Aristotle Capital’s Value Equity WM Composite posted a total return of 4.36% pure gross of fees (3.85% net of fees). Read more here.

SeekingAlpha·11:29

Edwards Lifesciences (EW) Has a Growth Runway Competitors May Struggle to Match

Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]

Yahoo·11:17EW